Nonbiologic drugs in pediatric rheumatology

Anand Prahalad Rao, Nutan Kamath

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.

Original languageEnglish
Title of host publicationPediatric Rheumatology
Subtitle of host publicationA Clinical Viewpoint
PublisherSpringer Science+Business Media Singapore Private Limited
Pages55-75
Number of pages21
ISBN (Electronic)9789811017506
ISBN (Print)9789811017490
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Rheumatology
Pediatrics
Drug Discovery
Vasculitis
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Quality of Life
Pharmacology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Rao, A. P., & Kamath, N. (2016). Nonbiologic drugs in pediatric rheumatology. In Pediatric Rheumatology: A Clinical Viewpoint (pp. 55-75). Springer Science+Business Media Singapore Private Limited. https://doi.org/10.1007/978-981-10-1750-6_7
Rao, Anand Prahalad ; Kamath, Nutan. / Nonbiologic drugs in pediatric rheumatology. Pediatric Rheumatology: A Clinical Viewpoint. Springer Science+Business Media Singapore Private Limited, 2016. pp. 55-75
@inbook{1c21ad3afa8c4247ad7f35ecaf6d9d59,
title = "Nonbiologic drugs in pediatric rheumatology",
abstract = "The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.",
author = "Rao, {Anand Prahalad} and Nutan Kamath",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-981-10-1750-6_7",
language = "English",
isbn = "9789811017490",
pages = "55--75",
booktitle = "Pediatric Rheumatology",
publisher = "Springer Science+Business Media Singapore Private Limited",
address = "Singapore",

}

Rao, AP & Kamath, N 2016, Nonbiologic drugs in pediatric rheumatology. in Pediatric Rheumatology: A Clinical Viewpoint. Springer Science+Business Media Singapore Private Limited, pp. 55-75. https://doi.org/10.1007/978-981-10-1750-6_7

Nonbiologic drugs in pediatric rheumatology. / Rao, Anand Prahalad; Kamath, Nutan.

Pediatric Rheumatology: A Clinical Viewpoint. Springer Science+Business Media Singapore Private Limited, 2016. p. 55-75.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Nonbiologic drugs in pediatric rheumatology

AU - Rao, Anand Prahalad

AU - Kamath, Nutan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.

AB - The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.

UR - http://www.scopus.com/inward/record.url?scp=85018607696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018607696&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-1750-6_7

DO - 10.1007/978-981-10-1750-6_7

M3 - Chapter

SN - 9789811017490

SP - 55

EP - 75

BT - Pediatric Rheumatology

PB - Springer Science+Business Media Singapore Private Limited

ER -

Rao AP, Kamath N. Nonbiologic drugs in pediatric rheumatology. In Pediatric Rheumatology: A Clinical Viewpoint. Springer Science+Business Media Singapore Private Limited. 2016. p. 55-75 https://doi.org/10.1007/978-981-10-1750-6_7